Gilead Sciences, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.gilead.com

Earnings Score
Moat Score
Safety Score

Market Cap $114.79B
PE 1007
Debt $25.06B
Cash $5.04B
EV $134.82B
FCF $9.43B

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$114.00M
EBIT	$822.00M
ROE	1%
ROA	2%
FCF	$9.43B
Equity	$18.48B
Growth Stability	2%
PE	1.01K
PEG	-93.82
PB	6.21
P/FCF	12.17
P/S	4.06
Price/Cash	0.04
Debt/Equity	1.36
Debt/FCF	2.66
Net Margins	-6%
Gross Margins	76%
Op. Margins	3%
Earnings CAGR	-23%
Sales Growth YoY	7%
Sales Growth QoQ	8%
Sales CAGR	-1%
FCF CAGR	-7%
Equity CAGR	1%
Earnings Stability	0.28
Earnings Growth YoY	-42%
Earnings Growth QoQ	-22%
Earnings CAGR 5Y	-11%

Sales CAGR 5Y	5%
FCF CAGR 5Y	-1%
Equity CAGR 5Y	-0%
Earnings CAGR 3Y	1%
Sales CAGR 3Y	1%
FCF CAGR 3Y	-9%
Equity CAGR 3Y	-4%
Market Cap	$114.79B
Revenue	$28.30B
Dividend Yield	3%
Payout Ratio	3K%
Assets	$54.53B
Total Debt	$25.06B
Cash	$5.04B
Shares Outstanding	1.25B
EV	134.82B
Earnings Score	4%
Moat Score	15%
Safety Score	59%
Final Score	26%
Working Capital	3.05B
Current Ratio	1.26
Gross Profit	$21.54B
Shares Growth 3y	-0%
Equity Growth QoQ	1%
Equity Growth YoY	-17%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.

SEC Filings

Direct access to Gilead Sciences, Inc. (GILD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Gilead Sciences, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Gilead Sciences, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -23%

Stability 28%

loading chart...

Gilead Sciences, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Gilead Sciences, Inc..

Years

Calculation mode

= $58B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$9.4B	$8.7B	$8.1B	$7.5B	$6.9B	$6.4B	$5.9B	$5.5B	$5.1B	$4.7B	$4.4B	$44B
DCF		$7.9B	$6.7B	$5.6B	$4.7B	$4B	$3.3B	$2.8B	$2.4B	$2B	$1.7B	$17B
Value	$58B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	48%	55%	44%	18%	25%	24%	0%	23%	17%	21%	-6%
ROA	-	43%	32%	21%	14%	10%	6%	15%	12%	12%	2%
ROE	-	95%	70%	23%	25%	24%	0%	29%	21%	25%	1%

Bad Net Margins (-6.15%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	1.18	1.65	3.21	4.02	3.26	4.54	2.61	3.3	3.61	2.66
Debt over Equity	0.81	1.21	1.36	1.77	1.4	1.2	1.87	1.34	1.29	1.17	1.36
Growth Stability	-	-	-	32%	45%	68%	2%	100%	100%	100%	2%

Neutral Debt/FCF ratio (2.66)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (1.36)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (2%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	31%	-7%	-14%	-15%	1%	10%	11%	-0%	-1%	5%
Earnings YoY growth	-	50%	-26%	-66%	18%	-2%	-98%	7K%	-26%	23%	-11%
Equity YoY growth	-	21%	1%	6%	5%	5%	-20%	16%	1%	7%	-0%
FCF YoY growth	-	60%	-19%	-29%	-34%	11%	-10%	44%	-23%	-11%	-1%